Changes in inflammatory biomarkers related to C-reactive protein and albumin in patients with terminal cancer receiving palliative care: a longitudinal study
Brazilian Journal of Oncology
Changes in inflammatory biomarkers related to C-reactive protein and albumin in patients with terminal cancer receiving palliative care: a longitudinal study
Autor Correspondente: Emanuelly Varea Maria Wiegert | [email protected]
Palavras-chave: C-reactive protein; albumin; biomarkers; inflammation; terminal cancer; palliative care
Resumos Cadastrados
Resumo Inglês:
BACKGROUND: Evidence about how inflammatory biomarkers vary during the end-stage cancer trajectory is lacking. This study investigates the longitudinal changes in albumin and C-reactive protein (CRP) levels, and CRP/albumin ratio (CAR) in patients with terminal cancer receiving palliative care in the last three months of life.
METHODS: This is a retrospective analysis of variables extracted from a prospective cohort study that included admitted patients to the exclusive Palliative Care Unit of the National Cancer Institute in Brazil. Routine blood examination results of albumin and CRP were recorded at 0-15 (T1), 16-30 (T2), 31-45 (T3), 46-60 (T4), 61-75 (T5), and 76-90 (T6) days before death and only patients with at least two measurements were included. Crude and adjusted linear mixed-effects regression models were performed to verify the relationships between the longitudinal trajectories of biomarkers and death.
RESULTS: A total of 1,635 patients were included. Median albumin was 3.00g/dL across the whole time-period analyzed (interquartile range, IQR: 2.50-3.60) and decreased with the approach of death, while median CRP was 9.31mg/L (IQR: 4.42-17.30) and CAR was 3.22 (IQR: 1.42-6.68), and both increased. The albumin (slope: all 0.01; p <0.001), CRP (slope: -0.10 to -0.13; p <0.001), and CAR (slope: -0.05 to -0.07; p <0.001) showed a linear dose-response relationship with death in crude and adjusted models tested.
CONCLUSIONS: The longitudinal change levels of inflammatory biomarkers worsen with the approach of death and could be used to predict end-stage in patients with terminal cancer.
